Tridax procumbens flavonoids promote osteoblast differentiation and bone formation. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Al Mamun, Md.; Hosen, Mohammad; Islam, Kamrul; Khatun, Amina; Alam, M.; Al-Bari, Md.
• Is Part Of: Biological research. Volume 48:Issue 1(2015)
• Page Start: 1
• Page End: 8
• Publication Date: 2015-12
• Subjects: Alkaline phosphatase -- Bone formation -- Osteoblast differentiation -- Osteocalcin; Biology, Experimental -- Periodicals; Biology -- Periodicals; 570.724
• DOI: 10.1186/s40659-015-0056-1
• Languages: English
• ISSNs: 0716-9760

Abstract

Abstract Background Tridax procumbens flavonoids (TPFs) are well known for their medicinal properties among local natives. Besides traditionally used for dropsy, anemia, arthritis, gout, asthma, ulcer, piles, and urinary problems, it is also used in treating gastric problems, body pain, and rheumatic pains of joints. TPFs have been reported to increase osteogenic functioning in mesenchymal stem cells. Our previous study showed that TPFs were significantly suppressed the RANKL-induced differentiation of osteoclasts and bone resorption. However, the effects of TPFs to promote osteoblasts differentiation and bone formation remain unclear. TPFs were isolated fromTridax procumbens and investigated for their effects on osteoblasts differentiation and bone formation by using primary mouse calvarial osteoblasts. Results TPFs promoted osteoblast differentiation in a dose-dependent manner demonstrated by up-regulation of alkaline phosphatase and osteocalcin. TPFs also upregulated osteoblast differentiation related genes, includingosteocalcin, osterix, andRunx2 in primary osteoblasts. TPFs treated primary osteoblast cells showed significant upregulation of bone morphogenetic proteins (BMPs) includingBmp -2, Bmp -4, andBmp -7 . Addition of noggin, a BMP specific-antagonist, inhibited TPFs induced upregulation of theosteocalcin, osterix, andRunx2 . Conclusion Our findings point towards the induction of osteoblast differentiation by TPFs and suggested that TPFs could be a potential anabolic agent to treat patients with bone loss-associated diseases such as osteoporosis.